Prognostic importance of prostate specific antigen in assessing histological grade of prostatic adenocarcinoma
Abstract
Background: Prostatic adenocarcinoma is one of the most common cancer occurring in the men above 50 years of age. Prostate specific antigen (PSA) is an important serum marker which helps in the diagnosis of prostatic adenocarcinoma and also aids in estimating the tumor grade.
Objective: To evaluate the correlation between serum PSA levels and Gleason’s histological grade of prostatic adenocarcinoma.
Methods: A retrospective study analysis was done for 128 patients whose transrectal ultrasonography (TRUS) guided prostate biopsy were studied in our hospital. The serum PSA levels were noted and compared with different Gleason histological grading in adenocarcinoma patients.
Results: Our study included 128 cases, out of which 86 cases were benign and 42 cases were malignant. Maximum numbers of benign and malignant lesions were in the age group of 60 – 69 years. Most of the malignant cases (80.95%) had PSA level above 20ng/ml. Histological grade III carcinomas were restricted to PSA levels of 50ng/ml and above, while grade I was restricted to PSA level of less than 10ng/ml and grade II carcinomas did not have any correlation with specific PSA levels.
Conclusion: Our study showed that there was significant correlation between serum PSA value and Gleasons histological grade of prostatic adenocarcinoma.
Downloads
References
2. Tchetgen MB, Oesterling JE. The role of prostate specific antigen in the evaluation of benign prostatic hyperplasia. Urol Clin North Am 1995;22(2):333-44. [PubMed]
3. Cooperberg MR, Pasta DJ, Elkin EP et al: The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 2005; 173: 1938.
4. Ahlering TE, Skarecky DW, McLaren CE, Weinberg AC: Seminal vesicle involvement in patients with D1 disease predicts early prostate specific antigen recurrence and metastasis after radical prostatectomy and early androgen ablation. Cancer 2002; 94(6):1648-1653.
5. D’Amico AV, Coleman CN: Role of interstitial radiotherapy in the management of clinically organ-confined prostate cancer: the jury is still out. J Clin Oncol 1996; 14:304-315. [PubMed]
6. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993 Jul;150(1):110-4. [PubMed]
7. Gomella LG, Liu XS, Trabulsi EJ, Kelly WK, Myers R, Showaltar T, Dicker A, Wender R. Screening for prostate cancer : the current evidence and guidelines controversy. Can J Urol. 2011 Oct;18(5):5875-83. [PubMed]
8. Lilja H. Biology of Prostate Specific Antigen. Urology 2003;62(5 suppl1):27-33.
9. Kuriyama M, Wang MC, Papsidero LD, Killian CS, Shimano T, Valenzuela L, Nishiura T, Murphy GP, Chu TM. Quantitation of Prostate Specific Antigen in serum by sensitive enzyme immunoassay. Cancer Research 1980;40(12):4658-62.
10. Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL. Effect of inflammation and benign prostatic hyperplasia on elevated serum Prostate Specific Antigen levels. J Urol 1995;154(2PE1):407-13. [PubMed]
11. Herschman JD, Smith DS, Catalona WJ. Effect of ejaculation on serum total and free prostate –specific antigen concentrations. Urology 1997;50(2):239-43. [PubMed]
12. Crawford ED, Schutz MJ, Clejan S, Drago J, Resnick MI, Chodak GW, Gomella GW, Austenfeld M, Stone NN, Miles BJ. The effect of digital rectal examination on Prostate-Specific Antigen levels. JAMA. 1992 Apr 22-29;267(16):2227-8.
13. Catalona W, Smith D, Ornstein D. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination. Enhancement of specificity with free PSA measurement. JAMA. 1997 May 14;277(18):1452-5. [PubMed]
14. Mikolacjyk SD, Catalona WJ, Evans CL, Linton HJ, Millar LS, Marker KM, Katir D, Amirkhan A, Rittenhouse HG. Proenzyme forms of Prostate-Specific antigen in serum improve the detection of Prostate cancer. Clin. Chem. 2004;50(6):1017-25. [PubMed]
15. Sladana Zivkovic. Correlation between prostatic specific antigen and histopathological difference of prostate carcinoma. Arch oncol 2004; 12(3): 148-51). [PubMed]
16. Lennox Anderson-Jackson, Donovan A McGrowder, Ruby Alexander-Lindo. Prostate Specific Antigen and Gleason Score in Men with Prostate Cancer at a Private Diagnostic Radiology Centre in Western Jamaica, Asian Pacific Journal of Cancer Prevention, Vol 13, 2012,1453-1456.